Stockreport

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2 [Seeking Alpha]

Tectonic Therapeutic, Inc.  (TECX) 
PDF TX45's engineered Fc-relaxin fusion overcomes prior failures by extending half-life, enabling durable hemodynamic improvements in the CpcPH subgroup per robust phase 1b [Read more]